'Array' of Ph II Asthma Data Spurs Stock
Shares of Array Biopharma Inc. hit a 52-week high of $7.20 Tuesday morning after the company reported positive findings from its randomized Phase II trial of oral CRTh2 antagonist ARRY-502 in mild to moderate persistent allergic asthma. The compound hit the primary endpoint – significant improvement in pre-bronchodilator forced expiratory volume in one second (FEV1), compared to placebo – across the study population and in a predefined Th2 biomarker subset that represented half of treated patients.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter